Related Experiment Video
Updated: Jul 11, 2026
07:51
The Application of 1% Methylene Blue Dye As a Single Technique in Breast Cancer Sentinel Node Biopsy
Published on: June 1, 2019
Sentinel lymph node biopsy in cutaneous melanoma.
Andrea Fernandes de Oliveira1, Ivan Dunshee de Abranches Oliveira Santos, Thaís Cardoso de Mello Tucunduva
1Unit of Skin Tumors, Plastic Surgery Division, Department of Surgery, Federal University of São Paulo, SP, Brazil. drandreafernandes@terra.com.br
Acta Cirurgica Brasileira
|October 10, 2007
Summary
Sentinel lymph node biopsy is a safe and effective method for staging cutaneous melanoma. A positive sentinel lymph node indicates a higher risk of tumor recurrence, guiding treatment decisions.
Area of Science:
- Oncology
- Dermatology
- Surgical Pathology
Background:
- Cutaneous melanoma staging is critical for prognosis and treatment planning.
- Sentinel lymph node biopsy (SLNB) is a minimally invasive procedure to assess regional lymph node metastasis.
Purpose of the Study:
- To evaluate the clinical significance of SLNB in patients diagnosed with early-stage cutaneous melanoma.
- To determine the correlation between SLNB status and melanoma recurrence rates.
Main Methods:
- Prospective follow-up of 90 patients with stage I and II melanoma who underwent SLNB.
- Data collection included patient demographics, tumor characteristics, SLNB results, and long-term outcomes.
Main Results:
- SLNB was positive in 32.5% of patients and negative in 67.5%.
- Tumor thickness positively correlated with SLNB positivity.
- Melanoma recurrence occurred in 43.5% of patients with positive SLNB versus only 7% with negative SLNB.
- No significant postoperative complications were reported.
Conclusions:
- SLNB is a safe procedure for staging cutaneous melanoma.
- SLNB status is a strong predictor of melanoma recurrence.
- SLNB effectively identifies patients who may benefit from further therapeutic lymphadenectomy.
